pemetrexed,carboplatin,paclitaxel,vinorelbine,nivolumab,cisplatin,docetaxel,gemcitabine,ipilimumab,pembrolizumab
merck,bms
['cm816', 'kn671']
cm816 vs kn671
dfs
pd-l1 &lt; 1% 0,85 0,77
1-49% 0,58 0,51
&gt; 50% 0,24 0,42
carbo 0,31 - none
cis 0,71 - 0,58
difference in pd-l1 allocation? real difference between short course na and year long peri-operative therapy? plat effect? i guess we still don t know. #asco2023 
Husband, father of 2, oncologist, marathoner, ultrarunner. Trains to inspire and works to push back limits of cancer treatment.